| Project/Area Number |
25220206
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (S)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Chemical biology
|
|---|
| Research Institution | Hokkaido University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
能祖 一裕 岡山大学, 医学部, 客員研究員 (10314668)
比能 洋 北海道大学, 先端生命科学研究院, 准教授 (70333333)
大山 力 弘前大学, 医学研究科, 教授 (80282135)
神山 俊哉 北海道大学, 医学研究院, 准教授 (80322816)
天野 麻穂 北海道大学, 創成研究機構 URAステーション, 特任助教 (80365808)
|
|---|
| Project Period (FY) |
2013-05-31 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥198,120,000 (Direct Cost: ¥152,400,000、Indirect Cost: ¥45,720,000)
Fiscal Year 2017: ¥33,410,000 (Direct Cost: ¥25,700,000、Indirect Cost: ¥7,710,000)
Fiscal Year 2016: ¥30,420,000 (Direct Cost: ¥23,400,000、Indirect Cost: ¥7,020,000)
Fiscal Year 2015: ¥32,760,000 (Direct Cost: ¥25,200,000、Indirect Cost: ¥7,560,000)
Fiscal Year 2014: ¥35,490,000 (Direct Cost: ¥27,300,000、Indirect Cost: ¥8,190,000)
Fiscal Year 2013: ¥66,040,000 (Direct Cost: ¥50,800,000、Indirect Cost: ¥15,240,000)
|
|---|
| Keywords | 癌バイオマーカー / 癌早期発見 / 糖鎖解析 / 大規模糖鎖構造解析 / 糖鎖工学 / 疾患糖鎖データベース / 抗体医薬 / 動的エピトープ / 糖鎖 / グライコブロッティング法 / グライコミクス / 疾患マーカー / 肝細胞癌 / 膵癌 / 腎細胞癌 / 早期診断法 / 診断薬探索 / ケミカルバイオロジー / 生体分子 / バイオマーカー |
|---|
| Outline of Final Research Achievements |
To establish the first disease-related glycome database, we have challenged the large-scale glycomics using more than 3500 patient’s sera provided from clinical teams. An innovative “automated glycan analytical system” facilitated rapid and large-scale serum glycomics and quantitative glycan profiling toward new biomarker discovery. For example, we succeeded in the discovery of novel N-glycan biomarkers as a significant recurrence factor based on whole serum glycan profiling of 369 patients of hepatocellular carcinoma(HCC)(Hepatology 2013 57, 2314-2325; Hepatology 2014 59, 355-356), N-glycans as promising prognostic biomarkers in renal cell carcinoma(The Prostate 2014 74, 1521-1529), and N-glycans associated significantly with metastatic castration-resistant status in prostate cancer(J. Urology 2014 191, 805-813). These results allowed the construction of the first database of the disease-related glycome feasible for the development of new diagnostic and therapeutic technologies.
|
| Assessment Rating |
Verification Result (Rating)
A-
|
Assessment Rating |
Result (Rating)
A: Progress in the research is steadily towards the initial goal. Expected research results are expected.
|
